Open AccessConsensus statement for the diagnosis and treatment of urticaria: A 2017 update
Author(s) -
Kiran Godse,
Abhishek De,
Vijay Zawar,
Bela Shah,
Mukesh Girdhar,
Murlidhar Rajagopalan,
D S Krupashankar
Publication year - 2018
Publication title -
indian journal of dermatology/indian journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.395
H-Index - 36
eISSN - 1998-3611
pISSN - 0019-5154
DOI - 10.4103/ijd.ijd_308_17
Subject(s) - medicine , guideline , omalizumab , statement (logic) , context (archaeology) , angioedema , intensive care medicine , quality of life (healthcare) , distress , dermatology , pathology , immunology , paleontology , clinical psychology , immunoglobulin e , nursing , political science , antibody , law , biology
This article is developed by the Skin Allergy Research Society of India for an updated evidence-based consensus statement for the management of urticaria, with a special reference to the Indian context. This guideline includes updated definition, causes, classification, and management of urticaria. Urticaria has a profound impact on the quality of life and causes immense distress to patients, necessitating effective treatment. One approach to manage urticaria is by identification and elimination of the underlying cause(s) and/or eliciting trigger(s) while the second one is by treatment for providing symptomatic relief. This guideline recommends the use of second-generation nonsedating H1-antihistamines as the first-line treatment. The dose can be increased up to four times to meet the expected results. In case patients still do not respond, appropriate treatment options can be selected depending on the associated medical condition, severity of the symptoms, affordability of the drugs, and accessibility of modern biologics such as omalizumab.